Creative Planning raised its position in shares of Alkermes PLC (NASDAQ:ALKS) by 4.8% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 18,877 shares of the company’s stock after buying an additional 865 shares during the period. Creative Planning’s holdings in Alkermes PLC were worth $1,094,000 at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in the stock. Daiwa SB Investments Ltd. acquired a new stake in Alkermes PLC during the second quarter worth $166,000. Greenwood Capital Associates LLC boosted its stake in Alkermes PLC by 2.4% in the first quarter. Greenwood Capital Associates LLC now owns 3,729 shares of the company’s stock worth $218,000 after buying an additional 89 shares in the last quarter. Mn Services Vermogensbeheer B.V. boosted its stake in Alkermes PLC by 5.9% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 4,053 shares of the company’s stock worth $222,000 after buying an additional 224 shares in the last quarter. Achmea Investment Management B.V. acquired a new stake in Alkermes PLC during the first quarter worth $247,000. Finally, Nomura Holdings Inc. purchased a new stake in Alkermes PLC during the first quarter valued at approximately $266,000. 97.24% of the stock is owned by hedge funds and other institutional investors.
Shares of Alkermes PLC (ALKS) opened at 57.62 on Thursday. The firm’s market capitalization is $8.83 billion. Alkermes PLC has a 52 week low of $41.93 and a 52 week high of $63.40. The company’s 50 day moving average price is $58.62 and its 200-day moving average price is $57.52.
Alkermes PLC (NASDAQ:ALKS) last posted its quarterly earnings data on Thursday, April 27th. The company reported ($0.31) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by $0.07. The company had revenue of $191.80 million during the quarter, compared to analyst estimates of $195.79 million. Alkermes PLC had a negative net margin of 25.61% and a negative return on equity of 9.76%. The business’s revenue for the quarter was up 22.3% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.16) earnings per share. On average, equities research analysts expect that Alkermes PLC will post ($0.04) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Alkermes PLC (NASDAQ:ALKS) Position Boosted by Creative Planning” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://sportsperspectives.com/2017/07/20/alkermes-plc-nasdaqalks-position-boosted-by-creative-planning.html.
Several research firms have recently commented on ALKS. J P Morgan Chase & Co set a $78.00 target price on Alkermes PLC and gave the company a “buy” rating in a research note on Saturday, July 1st. Leerink Swann cut Alkermes PLC from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $68.00 to $61.00 in a research note on Tuesday, June 13th. Credit Suisse Group reissued a “buy” rating and issued a $70.00 target price on shares of Alkermes PLC in a research note on Wednesday, June 7th. ValuEngine raised Alkermes PLC from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Cowen and Company reissued a “buy” rating on shares of Alkermes PLC in a research note on Friday, April 28th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $62.55.
In related news, Director Richard F. Pops sold 50,000 shares of the stock in a transaction on Wednesday, May 17th. The stock was sold at an average price of $58.19, for a total value of $2,909,500.00. Following the completion of the sale, the director now directly owns 680,406 shares in the company, valued at $39,592,825.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Michael J. Landine sold 10,000 shares of the stock in a transaction on Thursday, May 11th. The shares were sold at an average price of $57.01, for a total value of $570,100.00. Following the completion of the sale, the senior vice president now owns 172,370 shares of the company’s stock, valued at $9,826,813.70. The disclosure for this sale can be found here. Insiders sold 139,500 shares of company stock valued at $8,086,675 over the last 90 days. 5.34% of the stock is currently owned by company insiders.
About Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes PLC (NASDAQ:ALKS).
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.